Literature DB >> 25132760

Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells.

Xin-Lin Wu1, Kai-Jin Lin1, Ai-Ping Bai1, Wan-Xiang Wang1, Xing-Kai Meng1, Xiu-Lan Su1, Ming-Xing Hou1, Pei-De Dong1, Jun-Jing Zhang1, Zhao-Yang Wang1, Lin Shi1.   

Abstract

AIM: To investigate the effects of osteopontin (OPN) gene expression knockdown on colon cancer Lovo cells in vitro.
METHODS: Four candidate small interfering RNA (siRNA) constructs targeting the OPN gene and a scrambled control sequence (NC-siRNA) were synthesized and inserted into a pGPU6/GFP/Neo expression vector. After confirmation by restriction enzyme digestion and DNA sequencing, the recombinant plasmids were subsequently transfected into a human colon cancer cell line (Lovo) using a liposome transfection method. Stably transfected cells were maintained with G418 selection and referred to as Lovo-OPN-1, -2, -3, -4, and Lovo-NC cells. Knockdown efficiency of each of the four siRNA constructs was determined by real-time reverse transcription polymerase chain reaction assays and western blotting, and the construct with the most effective silencing was used for subsequent experiments. Cell proliferation, adhesion, and Matrigel invasion assays were performed to analyze the effects of OPN knockdown in stably transfected Lovo cells. The levels of four angiogenic factors, namely vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2, MMP-9 and urokinase plasminogen activator were detected by enzyme-linked immunosorbent assays (ELISA).
RESULTS: Recombinant vectors containing OPN-specific and scrambled siRNA sequences were successfully constructed and stably transfected into Lovo cells. Compared with the control Lovo and Lovo-NC cells, the levels of OPN mRNA and protein expression in Lovo-OPN-1, -2, -3, and -4 were significantly reduced (all P < 0.05), with the most efficient reduction observed in Lovo-OPN-4 cells (P < 0.05). Relative to untransfected Lovo cells, OPN mRNA expression levels in Lovo-NC and Lovo-OPN-4 cells were 1.008 ± 0.067 and 0.160 ± 0.023, respectively. The relative OPN protein expression levels in Lovo, Lovo-NC, and Lovo-OPN-4 cells were 3.024 ± 0.211, 2.974 ± 0.630, and 0.121 ± 0.008, respectively. Moreover, transfection with the scrambled sequence had no effect on the expression of OPN. After 24, 48, 72, and 96 h of cultivation, absorption values at 450 nm to assess proliferation of Lovo-OPN-4 cells were 0.210 ± 0.017, 0.247 ± 0.024, 0.314 ± 0.037, and 0.359 ± 0.043, respectively, which were significantly lower than those of Lovo (0.244 ± 0.031, 0.313 ± 0.024, 0.513 ± 0.048 and 0.783 ± 0.051) and Lovo-NC cells (0.241 ± 0.029, 0.309 ± 0.022, 0.563 ± 0.023, and 0.735 ± 0.067) (all P < 0.05). The absorption values at 595 nm, which were measured in a cell adhesion assay, showed that adhesion of Lovo-OPN-4 cells (0.215 ± 0.036) was significantly decreased compared to Lovo (0.490 ± 0.037) and Lovo-NC cells (0.462 ± 0.043) (P < 0.05). The number of invasive Lovo-OPN-4 cells (16.1 ± 1.9) was also significantly decreased compared to Lovo (49.9 ± 5.4) and Lovo-NC cells (48.8 ± 4.5) (P < 0.05). ELISA assays showed significant reductions in Lovo-OPN-4 cells compared to Lovo and Lovo-NC cells with regard to the expression of VEGF (1687.85 ± 167.84 ng/L vs 2348.54 ± 143.80 ng/L and 2284.39 ± 138.62 ng/L, respectively), MMP-2 (2966.07 ± 177.36 μg/L vs 4084.74 ± 349.54 μg/L and 4011.41 ± 424.48 μg/L, respectively), MMP-9 (3782.89 ± 300.64 μg/L vs 5062.90 ± 303.02 μg/L and 4986.38 ± 300.75 μg/L, respectively) and uPA (1152.69 ± 120.79 μg/L vs 1380.90 ± 147.25 μg/L and 1449.80 ± 189.92 μg/L, respectively) (all P < 0.05).
CONCLUSION: Knockdown of OPN gene expression suppresses colon cancer cell growth, adherence, invasion, and expression of angiogenic factors.

Entities:  

Keywords:  Angiogenesis; Colon carcinoma; Lovo cells; Osteopontin; RNA interference

Mesh:

Substances:

Year:  2014        PMID: 25132760      PMCID: PMC4130851          DOI: 10.3748/wjg.v20.i30.10440

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  35 in total

1.  Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis.

Authors:  Holger G Hass; Oliver Nehls; Juergen Jobst; Andrea Frilling; Ulrich Vogel; Stephan Kaiser
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

2.  Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner.

Authors:  Renee J Phillips; Karla J Helbig; Kylie H Van der Hoek; Devanshi Seth; Michael R Beard
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

3.  Tumor cell autocrine motility factor.

Authors:  L A Liotta; R Mandler; G Murano; D A Katz; R K Gordon; P K Chiang; E Schiffmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

4.  Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA.

Authors:  Rong-Xin Chen; Yun-Hong Xia; Tong-Chun Xue; Hong Zhang; Sheng-Long Ye
Journal:  Oncol Rep       Date:  2010-12-21       Impact factor: 3.906

5.  Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.

Authors:  A Oldberg; A Franzén; D Heinegård
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

6.  A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.

Authors:  Hao Liu; Anmin Chen; Fengjing Guo; Lin Yuan
Journal:  Cancer Lett       Date:  2010-03-06       Impact factor: 8.679

7.  Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.

Authors:  Tatiana M Tilli; Kivvi D Mello; Luciana B Ferreira; Aline R Matos; Maria Thereza S Accioly; Paulo A S Faria; Akeila Bellahcène; Vincent Castronovo; Etel R Gimba
Journal:  Prostate       Date:  2012-04-11       Impact factor: 4.104

8.  Inhibition of osteopontin suppresses in vitro and in vivo angiogenesis in endometrial cancer.

Authors:  Xue-lian Du; Tao Jiang; Xiu-gui Sheng; Rong Gao; Qing-shui Li
Journal:  Gynecol Oncol       Date:  2009-09-23       Impact factor: 5.482

9.  Osteopontin-enhanced hepatic metastasis of colorectal cancer cells.

Authors:  Jianjin Huang; Chi Pan; Hanguang Hu; Shu Zheng; Ling Ding
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  Role of osteopontin in breast cancer patients.

Authors:  Antonio Macrì; Antonino Versaci; Giuseppe Lupo; Giuseppe Trimarchi; Chiara Tomasello; Saverio Loddo; Giuseppe Sfuncia; Rocco Caminiti; Diana Teti; Ciro Famulari
Journal:  Tumori       Date:  2009 Jan-Feb
View more
  18 in total

1.  MicroRNA-125a reduces proliferation and invasion of oral squamous cell carcinoma cells by targeting estrogen-related receptor α: implications for cancer therapeutics.

Authors:  Ankana Tiwari; Swamy Shivananda; Kodaganur S Gopinath; Arun Kumar
Journal:  J Biol Chem       Date:  2014-09-29       Impact factor: 5.157

Review 2.  Comparative analysis of gene expression profiles of OPN signaling pathway in four kinds of liver diseases.

Authors:  Gaiping Wang; Shasha Chen; Congcong Zhao; Xiaofang Li; Weiming Zhao; Jing Yang; Cuifang Chang; Cunshuan Xu
Journal:  J Genet       Date:  2016-09       Impact factor: 1.166

3.  Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases.

Authors:  Akio Shiomi; Masatoshi Kusuhara; Takashi Sugino; Teiichi Sugiura; Keiichi Ohshima; Takeshi Nagashima; Kenichi Urakami; Masakuni Serizawa; Hideyuki Saya; Ken Yamaguchi
Journal:  Oncol Lett       Date:  2021-04-12       Impact factor: 2.967

4.  Transcriptomic and proteomic insights into patulin mycotoxin-induced cancer-like phenotypes in normal intestinal epithelial cells.

Authors:  Neha Singh; Indra Dev; Saurabh Pal; Sanjeev Kumar Yadav; Mohammed M Idris; Kausar Mahmood Ansari
Journal:  Mol Cell Biochem       Date:  2022-02-12       Impact factor: 3.396

5.  SPP1 facilitates cell migration and invasion by targeting COL11A1 in lung adenocarcinoma.

Authors:  Xuan Yi; Linlin Luo; Yanzhen Zhu; Hong Deng; Huitian Liao; Yang Shen; Yan Zheng
Journal:  Cancer Cell Int       Date:  2022-10-20       Impact factor: 6.429

6.  Wnt/catenin β1/microRNA 183 predicts recurrence and prognosis of patients with colorectal cancer.

Authors:  Yuzhuo Chen; Weiliang Song
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

7.  Characterisation of colonic dysplasia-like epithelial atypia in murine colitis.

Authors:  Sarron Randall-Demllo; Ruchira Fernando; Terry Brain; Sukhwinder Singh Sohal; Anthony L Cook; Nuri Guven; Dale Kunde; Kevin Spring; Rajaraman Eri
Journal:  World J Gastroenterol       Date:  2016-10-07       Impact factor: 5.742

8.  Proangiogenic functions of an RGD-SLAY-containing osteopontin icosamer peptide in HUVECs and in the postischemic brain.

Authors:  Hahnbie Lee; Yin-Chuan Jin; Seung-Woo Kim; Il-Doo Kim; Hye-Kyung Lee; Ja-Kyeong Lee
Journal:  Exp Mol Med       Date:  2018-01-19       Impact factor: 8.718

9.  Silencing Osteopontin Expression Inhibits Proliferation, Invasion and Induce Altered Protein Expression in Melanoma Cells.

Authors:  Tímea Kiss; Krisztina Jámbor; Viktória Koroknai; István Szász; Helga Bárdos; Attila Mokánszki; Róza Ádány; Margit Balázs
Journal:  Pathol Oncol Res       Date:  2021-03-05       Impact factor: 3.201

10.  Genomic amplification upregulates estrogen-related receptor alpha and its depletion inhibits oral squamous cell carcinoma tumors in vivo.

Authors:  Ankana Tiwari; Shivananda Swamy; Kodaganur S Gopinath; Arun Kumar
Journal:  Sci Rep       Date:  2015-12-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.